Boston – Cresa announced that it has negotiated a long-term lease commitment for over 100,000sf at Centerpoint, located at 41 Seyon St. in Waltham on behalf of Generation Bio Co.
Generation Bio will use the new space to build an in-house current good manufacturing practice (cGMP) compliant facility to scale closed-ended DNA (ceDNA) manufacturing using rapid enzymatic synthesis (RES). The facility will be designed to provide cGMP-compliant clinical and initial commercial supply and also house expanded capacity for research production and process development activities. Cresa provided workplace solutions, labor and financial analytics, transaction management, and stakeholder decision support, resulting in a holistic strategy and ultimately an excellent outcome for Generation Bio.
The company has signed a lease agreement to build out a state-of-the-art cGMP facility to scale RES for clinical and initial commercial supply. In addition, the new facility will house expanded capacity for research production and process development activities. The facility is expected to be operational in 2023, enabling an Investigational New Drug (IND) application and clinical development for the company’s lead hemophilia A program in 2023. The company is using existing infrastructure for RES production of research material.
Paul Delaney, Vicki Keenan, and John Coakley of Cresa Boston negotiated the lease for Generation Bio, and Matt Malatesta, Mark Roth, Brendan Daly, and Brianna Piacitelli of Newmark represented the landlord (HRP). The project team includes Hilco Redevelopment Partners as landlord, TRIA as architect, Commodore Builders as construction manager, and Hereva as OPM.
